Home/Pipeline/RG6356 (RO7434656)

RG6356 (RO7434656)

Acute Myeloid Leukemia

Phase IIIActiveNCT05028751

Key Facts

Indication
Acute Myeloid Leukemia
Phase
Phase III
Status
Active
Company

About Chugai Pharmaceutical

Chugai Pharmaceutical's mission is to create innovative, best-in-class therapeutics that contribute to human health worldwide, with a strategic focus on oncology and niche specialty areas. Its defining achievement is the construction of a highly successful, decades-long strategic alliance with Roche, which provides a unique two-way pipeline flow, global scale, and financial stability. The company's strategy centers on maintaining a powerful independent R&D engine to generate proprietary assets while simultaneously co-developing and commercializing Roche's global portfolio in its key markets. This model has established Chugai as Japan's premier biopharmaceutical innovator and a vital node in Roche's global network.

View full company profile

Other Acute Myeloid Leukemia Drugs